LOTTE (004990) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
29 Mar, 2026Executive summary
Revenue for 4Q25 was KRW 37,569 billion, nearly flat year-over-year, with full-year revenue down 1.4% to KRW 155,396 billion.
Operating loss widened in 4Q25 due to raw material cost pressures and one-off expenses, but net loss decreased year-over-year, aided by improved equity method investee performance.
F&B segment saw revenue growth from global expansion, while retail revenue declined due to store efficiency initiatives.
Shareholder returns increased, with a higher dividend per share and a 5% treasury stock retirement.
Financial highlights
4Q25 consolidated revenue: KRW 37,569 billion (▲0.3% YoY); full-year: KRW 155,396 billion (▲1.4% YoY).
4Q25 operating loss: KRW 106 billion (loss widened YoY); full-year operating profit: KRW 239 billion (▲29.7% YoY).
4Q25 net loss: KRW 419 billion (loss decreased YoY); full-year net loss: KRW 595 billion (loss decreased YoY).
F&B segment 4Q25 revenue up 1.9% YoY; retail segment revenue down 8.2% YoY.
Dividend per share increased to KRW 1,250 (+4.2% YoY); payout ratio 127%.
Outlook and guidance
Continued focus on enhancing core brand value, optimizing operations, and global expansion in F&B.
Retail to pursue store efficiency and customer-centric strategies.
New business investments in biologics, EV charging, secondary battery materials, and metaverse platforms.
Latest events from LOTTE
- Targeting 35%+ shareholder return rate and growth via new businesses and ESG leadership.004990
Corporate Value-up Plan presentation15 Jan 2026 - 2Q25 saw lower revenue and profit, but 2H25 outlook is positive on expected consumption recovery.004990
Q2 202515 Jan 2026 - Record sales offset by profit decline from higher costs and affiliate losses; growth plans continue.004990
Q4 202415 Jan 2026 - Record revenue from F&B growth, but net profit negative amid equity losses and retail headwinds.004990
Q2 202415 Jan 2026 - Record revenue but net loss due to cost pressures; major biologics investments continue.004990
Q3 202415 Jan 2026 - Pursuing balanced growth via restructuring, global expansion, and new growth investments.004990
IR Day presentation15 Jan 2026 - Revenue and profit fell sharply, but global F&B and GRS growth offset weak domestic demand.004990
Q1 202515 Jan 2026 - Stable revenue and higher operating profit driven by F&B growth and retail restructuring.004990
Q3 202515 Jan 2026